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A B S T R A C T
Many studies had been focused on designing tacrolimus sustained release preparations based
on solid dispersion technique, but no one had tried to employ mesoporous silica as the carrier
material to realize this goal. The purpose of this study was to develop a novel, simple and
environmental friendly drug loading method with mesoporous silica to obtain tacrolimus
sustained-release preparation. Tacrolimus was firstly dissolved in the molten mixed lipid
composed of Compritol 888 ATO and Gelucire 50/13 to prepare a drug loaded lipid-based
drug delivery systems (LBDDS), then the liquid LBDDS was adsorbed by mesoporous silica
to transfer the liquid into solid powder, ie. the tacrolimus sustained release silica-lipid hybrid
(SLH). The SLH was characterized by SEM, CLSM, XRPD and DSC, and the in vitro drug release
was tested using a paddle method. SEM and CLSM observation showed that the LBDDS was
efficiently distributed throughout the pores of the silica. The results of DSC and XRPD il-
lustrated that the lipid existed inside the silica at amorphous state. The drug-loaded SLH
showed good flowability, compressibility, compactibilty and two-phase in vitro drug release
process within 24 hours, which did not change obviously even after storage at 40 °C for 10 d.
The present study provided a novel and simple method to prepare tacrolimus sustained
release powder, which provided a feasible solution to solidify the liquid LBDDS of not only
extended drug release behavior, but also improved stability and micromeritic properties.
© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Tacrolimus, previously known as FK506, is a macrolide immu-
nosuppressant produced by Streptomyces tsukubaensis. Due to
its potent immunosuppressive activity, low dosage, high organ
survival rate and low incidence of acute rejection rate,
tacrolimus is clinically used in the prophylaxis of organ re-
jection after hepatic and renal transplantation procedures [1].
As a BCS class II drug, the poor water solubility of tacrolimus
greatly limited its oral bioavailability.Thus, increasing the solu-
bility or dissolution of tacrolimus was one of the key problems
in improving oral bioavailability, and many studies have been
devoted to the modification of various drug delivery systems,
including solid dispersion [2,3], nanoparticles [4–6], liposome
[7,8], and self-emulsification [9]. Tacrolimus extended release
preparations attracted great attention in both clinical prac-
tice and drug development due to its superior therapeutic
profits, such as decreased ratio of peak/trough blood drug level,
improved oral bioavailability and eliminated need for fre-
quent dosing.There were already two modified release products
of tacrolimus approved and marketed worldwide. A once-
daily tacrolimus sustained release capsule supplied by Astellas
Pharma Inc was approved in Europe (Advagraf®) and Japan
(Graceptor®) in 2007 [10,11]. After that, tacrolimus sustained-
release tablet produced by Veloxis Pharmaceuticals was approved
both in Europe and USA with the brand names Envarsus® and
Envarsus®XR, respectively. In addition, there was an explo-
sion of interest in developing tacrolimus extended release
preparations in recent years. Cho et al. had focused on the de-
velopment of novel fast-dissolving tacrolimus solid dispersion-
loaded prolonged release tablet. Wang et al. reported a novel
gastro-retentive sustained-release tablet of tacrolimus based
on self-microemulsifying mixture [12].
Lipid excipients aroused great interest from drug formu-
lation researchers owing to their ability of providing solutions
to drug delivery challenges, such as low drug solubility and dis-
solution rate, poor oral absorption of water-insoluble drugs, as
well as the simplified and safety manufacturing processes, and
so on [13–15]. For poorly water-soluble drugs, lipid-based drug
delivery systems (LBDDS) unveiled distinguish prospects as it
can mimic the food effect via creating a lipophilic microen-
vironment within the gastrointestinal tract, thus enhancing the
solubilization of poorly water-soluble drug molecules and pro-
viding a concentration gradient that drive the absorption of
drug molecules in the intestinal tract [16–20]. One of the major
disadvantages of LBDDS lies in its liquid or low melting-
point semi-solid state (eg. lipid solutions, suspensions, and
emulsions) at ambient environment, which may result in physi-
cochemical instability during storage, thus greatly limited
applications of LBDDS [21,22].
Mesoporous materials with tunable pore size of 2 nm to
50 nm, large surface area and porosity, and high adsorbing ca-
pacity have been selected as ideal carriers for both fast and
extend drug release. Mesoporous silica was widely investi-
gated as drug delivery systems since Vallet-Regi firstly used it
for loading of drug in 2001 [23–27].The use of mesoporous silica
in drug delivery systems is mainly due to its excellent adsorp-
tive properties. In previous reports, organic solvent solution
soaking method was often used to load poorly water-soluble
drugs for fast drug release. Wang et al. achieved sustained
release of drug by employing supercritical fluid technique to
load poorly water-soluble drug deep into the pore channels of
mesoporous silica [25]. It is the physical interaction between
silica and adsorbed guest molecules that delays drug release
[28]. Mesoporous silica can also be used as a carrier of LBDDS
via physical adsorption to convert the liquid or semi-solid state
LBDDS into solid powder and formed silica-lipid hybrid (SLH)
with improved the flowability, compressibility and
compactibility. The powdered SLH combined the well-known
advantages of LBDDS with those of solid dosage forms, and
what’s more, it bore the ability to greatly improve the physi-
cochemical stability of LBDDS [29].
Till now, there is no report on the use of lipid excipients
and mesoporous silica as the organic/inorganic hybrid carrier
to achieve solidified LBDDS for sustained tacrolimus release.
In this study, tacrolimus was dissolved in a mixture of molten
lipids composed of glyceryl behenate and stearoyl polyoxyl-
32 glycerides to obtain drug loaded LBDDS, and then
mesoporous silica was used to adsorb the liquid LBDDS to
obtain SLH powder. The physicochemical properties of SLH
powder and its in vitro drug release were studied. It is desir-
able to achieve a novel, simple and solvent-free technique to
fabricate tacrolimus sustained release preparations with this
method.
2. Materials and methods
2.1. Materials
Tacrolimus (Chinese Pharmacopeia) was a gift from Zhejiang
Hisun Pharmaceutical Co. Ltd (Jiangsu, China); glyceryl behenate
(Compritol 888 ATO) and stearoyl polyoxyl-32 glycerides
(Gelucire 50/13) were kindly donated by Gattefossé (France);
mesoporous silica (Parteck SLC) was provided by Merck & Co.
Inc (Germany). Tacrolimus capsules: brand name Prograf; stan-
dard 1 mg/capsule; batch number 1E2201A. All other chemicals
used were of chemical or analytical grades and used as received.
2.2. Preparation of tacrolimus loaded LBDDS and SLH
Tacrolimus loaded SLH was prepared in a process of two-
steps, ie., preparation of drug-loaded LBDDS and the
solidification of LBDDS to form the drug-loaded SLH as de-
scribed below. (1) tacrolimus, and/or Compritol 888 ATO and
Gelucire 50/13 were accurately weighed according to the for-
mulations listed in Table 1, and placed into a glass round bottom
flask and heated at 80 °C with constant stirring until all the
excipients were melted; then tacrolimus was added into the
molten mixture at 70 °C with stirring to form a homogenous
mixture. (2) The mesoporous silica was mixed with the above
molten mixture, and the molten mixture was adsorbed into
the pores inside the silica under decreased pressure. The
mixture was stirred for another half an hour at 70 °C and then
cooled down to room temperature to form the final solid hybrid
mixture. The lipid free, tacrolimus loaded mesoporous silica
was prepared with similar method using ethanol as the solvent
and fabricated at room temperature.
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2.3. Scanning electron microscopy (SEM) observation
The mesoporous silica, drug-loaded SLH and drug-loaded SLH
after in vitro drug release were spattered with gold, their mor-
phologies were observed using a S-3400 SEM (Hitachi, Japan)
at 5.0 KV electron acceleration voltage.
2.4. Confocal laser scanning microscopy
microphotographs (CLSM)
Coumarin, a fluorescent dye, was loaded into SLH as the model
molecule instead of tacrolimus to observe the distribution of
drug inside the mesoporous carrier. Briefly, about 1 μg of cou-
marin was dissolved in 100 mg of lipid mixture molten at 70 °C,
the mixture was then adsorbed into 300 mg of mesoporous
silica. Confocal laser scanning microscopic images of the
coumarin-loaded mesoporous silica were taken with LSM 710
and Axio Inverted Microscope (ZEISS, Germany), and laser of
464 nm wavelength was used to excite the fluorescence
coumarin.
2.5. X-ray powder diffraction (XRPD)
The crystalline characteristics of tacrolimus, drug-loaded LBDDS,
mesoporous silica and drug-loaded SLH were determined by
XRD-6000 X-ray Powder Diffractometry (Shimadzu, Japan) at
40 kV and 40 mA using Cu Kα radiation.The samples were mea-
sured in the 2θ range between 5° and 60° at a scan rate of 2.8°
per second with step of 0.0167°.
2.6. Differential scanning calorimetry (DSC)
The physical state of tacrolimus, drug-loaded LBDDS,
mesoporous silica and drug-loaded SLH were measured with
DSC-6 (Mettler-Toledo, Switzerland). Samples (about 5 mg) were
weighed accurately and sealed in an aluminum pan and the
DSC curves were determined at a heating rate of 10 °C/min from
25 °C to 180 °C under N2 gas purge of 40 ml/min, and an empty
pan was used as reference.
2.7. In vitro drug release
The in vitro release test was performed using the paddle method
described in Chinese Pharmacopoeia (2015) with small beakers
using a ZRS-8G Dissolution Apparatus (Tianda Tianfa Technol-
ogy Co. Ltd., China). One hundred milliliters of distilled water
containing 0.005% hydroxypropyl cellulose (adjust pH to 4.5 with
phosphoric acid) was used as the dissolution media accord-
ing to USP 35, and the stirring speed was set at 50 rpm/min.
Samples equivalented to 1 mg of tacrolimus was placed in the
dissolution medium, 3.0 ml of the medium was withdrawn from
the beakers and replaced with the equal volume of fresh dis-
solution medium at pre-determined time intervals.The medium
was filtered through a membrane filter of 0.45 μm pore size
(Millipore, USA), the content of tacrolimus was then assayed
by L-2000 high performance liquid chromatography (HPLC)
(Hitachi, Tokyo, Japan), and the UV-vis detector was set at
210 nm. Tacrolimus was analyzed using Dikma ODS C18 chro-
matography column (200 mm × 4.6 mm, 5 μm).The mobile phase
consisted of acetonitrile and distilled water (75:25, v/v) and was
pumped at a flow rate of 1.0 ml/min at the temperature of 50 °C.
Validation of assay method showed good linearity in the con-
centration range of 0.5 μg/ml to 12.0 μg/ml (A = 14669C+13.799,
R2 = 0.999) and precision (RSD < 2%).
2.8. Properties of the powder
2.8.1. Density
Bulk, tapped, and true densities of the mesoporous silica
powder, drug-loaded LBDDS of formulation No. 1 and drug-
loaded SLH of formulation No. 3 were measured with methods
in literatures [30,31]. About 0.5~1.0 g mesoporous silica, LBDDS
or SLH were placed in a graduated cylinder to measure the bulk
and tapped density. Bulk density was calculated by the equa-
tion mass/volume before tapping while the tapped density was
obtained after 100 taps to allow the powder volume to plateau.
The true density was measured as follows: about 0.5~1.0 g
mesoporous silica, drug-loaded LBDDS or drug-loaded SLH were
compressed into tablet at maximum pressure, and the true
density was calculated by mass/volume of the tablet.
2.8.2. Flowability
Two methods were used to evaluate the flowability of the
powders, ie. Carr’s index and Hausner ratio, and the tilt method.
The Carr’s index and Hausner ratio could be calculated by
Eq. 1 and Eq. 2, respectively [32].
Carr’s index tapped density bulk density tapped density= −( )
(Eq. 1)
Hausner ratio tapped density bulk density= (Eq. 2)
And to measure the angle of repose, the cylindrical con-
tainer with powder samples which took up about 1/3 of the
container volume was fluctuated, after the powder remained
repose, the angle formed by the surface of the powder was
defined as the angle of repose.
2.8.3. Compressibility
About 300 mg of pure silica or drug-loaded SLH powder was
accurately weighed, and the volume of the powder (V0) was de-
termined. Then, the powders were compressed into flat tablet
with a diameter of 13 mm using a single punch press at pres-
sure P and the maximum pressure, respectively, and the
Table 1 – Formulations of tacrolimus loaded LBDDS and
SLH.
No. Ingredients, mg
Tacrolimus Compritol888
ATO
Gelucire
50/13
Mesoporous
Silica
1 20 140 60
2 20 70 30 360
3 20 140 60 660
4 20 210 90 960
5 20 120 80 660
6 20 160 40 660
7 20 140 60 220
8 20 140 60 440
9 20 140 60 880
10 20 800
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corresponded volumes of the samples (V and V∞) were deter-
mined. The slope (c15) calculated according to Heckel equation
(Eq. 3) was used to evaluate the powder compressibility.
ln lnV V V c P V V V−( ) = + −( )∞ ∞15 0 0 (Eq. 3)
3. Results and discussion
3.1. Morphology and physicochemical properties
The SEM images of mesoporous silica, drug-loaded SLH, and
drug-loaded SLH after in vitro drug release test were shown in
Fig. 1, A, B, and C. The mesoporous silica was made up of small
particles with irregular shapes and smooth surfaces, with par-
ticle sizes ranging from 5 μm to 25 μm.The surface morphology,
size and size distribution of the drug-loaded SLH were similar
with those of the mesoporous silica except for a small amount
of residual lipid material adhered on the surface. The CLSM
image provided further insight into the drug distribution inside
the mesoporous silica particles (Fig. 1,D). Green fluorescence
(owing to coumarin) was clearly visualized to be uniformly con-
centrated inside the silica, which meant the active drug can
be efficiently adsorbed into the mesoporous silica together with
the hot-melt LBDDS.
Fig. 2 showed the DSC curves and the XRPD patterns of
tacrolimus, drug-loaded LBDDS, mesoporous silica and drug-
loaded SLH, respectively. Tacrolimus showed an endothermic
peak at 130 °C that corresponded to its melting point. The DSC
curve of drug-loaded LBDDS did not show the endothermic peak
of tacrolimus, and it exhibited two endothermal peaks, which
corresponded to the melting point of Compritol 888 ATO (~70 °C)
and Gelucire 50/13 (~50 °C), respectively. However, there were
no peaks of tacrolimus, Compritol 888 ATO or Gelucire 50/13
in the DSC curve of drug-loaded SLH. As the drug content in
both drug-loaded LBDDS and drug-loaded SLH was very low
(9.1% and 2.3% respectively), the results of DSC analysis could
only indicate that LBDDS existed in the mesoporous silica at
amorphous state.
Fig. 1 – SEM images of mesoporous silica (A), drug-loaded SLH (B) and drug-loaded SLH after in vitro drug release test (C),
and CLSM image of the coumarin loaded SLH (D, the insert showed an enlarged image).
Fig. 2 – DSC curves (A) and XPRD patterns (B) of drug-
loaded LBDDS (a), mesoporous silica (b), drug-loaded SLH
(c) and tacrolimus(d).
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XRPD analysis could clearly describe the crystalline degree
of materials. As seen in Fig. 2, B, the XRPD pattern of tacrolimus
displayed multi-peaks in the range between 2θ = 5° and 2θ = 40°,
while that of drug-loaded LBDDS had 3 peaks at 2θ = 19°,
2θ = 21°, and 2θ = 23°, respectively, which could be attributed
to the presence of crystalline lipid. The mesoporous silica and
drug-loaded SLH showed no typical crystal peak, which indi-
cated that the drug-loaded LBDDS (mainly the lipids) existed
inside the mesoporous silica at amorphous state. Due to the
extremely low content of tacrolimus, the XRPD results could
only give information that the mixed lipids in mesoporous silica
was presented at amorphous state, which was different to the
crystalline state in LBDDS.
3.2. In vitro release of tacrolimus
The in vitro release test were conducted with the formula-
tions obtained, and the results were compared with that of
commercial capsules (Table 1, Fig. 3.). As shown in Fig. 3, A,
for the raw tacrolimus, only about 50% of the drug could release
within 24 h, while the drug of commercial capsule released com-
pletely within 1 h. The drug-loaded LBDDS and drug-loaded
mesoporous silica free of lipids demonstrated fast release of
100% within 2 h and 0.5 h, respectively. Drug-loaded SLH (for-
mulation No.3) that was obtained by co-loading of the lipid
matrix and tacrolimus into the pores of mesoporous silica
showed extended and complete drug release at 24 h, which may
be attributed to the retardation effect of the semisolid lipids
matrix and the mesopores of the silica, as well as the solid dis-
persion nature of the lipid carrier.
The mixed lipids composed of high melting point and weak
hydrophilicity Compritol 888 ATO and low melting point and
better hydrophilicity Gelucire 50/13 were used as the carrier
material of tacrolimus loaded LBBDS to improve the solubility/
dissolution of tacrolimus significantly. The mixed lipid at hot-
melt state (about 70 °C dependent on the ratio of the two lipids)
can readily dissolve water-insoluble tacrolimus, and after cooling
down to room temperature forms drug loaded solid disper-
sion. In our article, mesoporous silica was directly introduced
into the hot-melt lipid, the lipid and the tacrolimus dissolved
in were then adsorbed inside the mesopores under vacuum.
After totally sucked in, the finally obtained SLH was solid
powder of good flowability, instead of wax-like, semi-solid state
of the mixed lipid. Different to the volatile organic solvents com-
monly used for loading water-insoluble active drugs into
mesoporous materials in previous studies, the hot-melt lipid
was not only used as the solvent to tacrolimus, but also the
retardant material to sustain drug release. The advantages of
such organic solvent-free technique also include simple, low
cost/profit ratio, and its being environmental friendly, and by
varying the ratio of the two lipids, it will be easy to adjust the
melting points and drug release rate.
One of the commonly faced difficulties in developing a lipid
based modified release formulation may lie in the instability
of the lipid crystalline, and consequent changes on the melting
points of the carrier material and even the drug release be-
havior after storage under ambient or challenged conditions.
Many research had been devoted to investigate the impact
of time and storage condition on drug release of lipid-based
modified release preparations. Normally, the lipid excipients
were glyceride mixtures and they naturally bore polymor-
phism that was the main reason of changed drug release
behavior over time due to the crystalline transformation. Fig. 3,
B indicated significant change on in vitro drug release behav-
ior of tacrolimus loaded LBDDS (formulation No.1) after being
stored at 40 °C, a high temperature, challenge condition. Ironi-
cally, no apparent differences on drug release behavior of drug-
loaded SLH (formulation No.3) were observed again after being
stored for 10 d (Fig. 3, C). The similarity factor f2 of the two
release curves was calculated by Eq. 4,
f R Tj j
j
n
2
2
1
0 5
50 1 1 100= × + −( )⎡⎣⎢
⎤
⎦⎥
×
⎧
⎨⎪
⎩⎪
⎫
⎬⎪
⎭⎪=
−
∑log
.
n (Eq. 4)
The value of f2 was 59.6, higher than 50, which demon-
strated similar of the two release curves. This result also
indicated improved stability by loading the lipid carrier inside
mesoporous carrier. As the LBDDS was dispersed in the chan-
nels of mesoporous silica at amorphous state, it was separated
and restricted inside huge amount of fine pores in the silica,
thus the crystal growth of LBDDS or re-crystallization was
greatly inhibited. In addition, the LBDDS adsorbed in the pore
was avoided the contact with atmospheric oxygen, which would
be helpful to improve the durability against oxidative degra-
dation [33,34].
Fig. 3 – The in vitro release of raw tacrolimus, commercial capsules, drug-loaded mesoporous silica, drug-loaded LBDDS and
drug-loaded SLH (n = 3) (A), the in vitro release of drug-loaded LBDDS (B) and drug-loaded SLH (C) before and after being
stored at 40 °C for 10 d (n = 3).
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The ratios of drug to mixed lipids and Compritol 888 ATO
to Gelucire 50/13 had a marked influence on drug release be-
haviors (Fig. 4, A and B). With the decrease of the ratios of drug
to lipids, the release of tacrolimus from SLH remarkably de-
creased. When the ratio of drug to lipids was 1:10, tacrolimus
released slowly and completely at 24 h from the SLHs, and
higher or lower ratios resulted in fast release or uncom-
pleted release even after 24 h (Fig. 4, A). The more Compritol
888 ATO in the mixed lipids, the slower the observed drug
release rate was (Fig. 4, B).
Since the lipids used also played the role of retarding ma-
terial to sustain drug release, too high ratio of mixed lipids to
tacrolimus used would lead to stronger inhibition effect which
limited the diffusion of tacrolimus outward and resulted in an
uncompleted release, while too low ratio was not enough to
retard drug diffusion into medium and thus resulted in fast
release. As it is well known, the melting point and the HLB
values of the lipids are the most important properties when
considering lipid excipients for extended drug release formu-
lation. Lipids with high melting point and low HLB value, such
as Compritol 888 ATO, are more effective in retarding drug
release [35–37]. As a hydrophobic lipid with a melting point of
74 °C and a HLB value of 2, Compritol 888 ATO may obviously
inhibit the diffusion of release medium into LBDDS, and sub-
sequently retard the drug release. On the contrary, Gelucire 50/
13 is a more hydrophilic lipid with a melting point of 50 °C and
a HLB value of 13 [38,39], which can dissolve rapidly as soon
as it comes into contact with the release medium and en-
hances the dissolution of loaded drug.
The ratio of lipids to mesoporous silica was another im-
portant factor that greatly influenced drug release behavior from
the SLHs as presented in Fig. 4, C. As the results showed the
co-loading of the lipid matrix and tacrolimus into mesoporous
silica was effective in retarding drug release, and the lower ratio
of lipids to mesoporous silica corresponded to slower drug
release. When the ratio of lipids to silica was 1:1, the formu-
lation showed a relatively fast drug release of about 90% within
2 h, while with the increase of silica, for example the ratios
lower than 1:2, drug release began to display the sustained
release behavior. What is more, there was no obvious differ-
ence when the ratios were 1:3 and 1:4. Thus, the significance
of the ratio of lipids to silica in designing optimal sustained-
release composition was highlighted beyond doubt. This was
because if the amount of the silica was not enough to adsorb
all the lipids completely (eg. the ratio of lipid to silica higher
than 1:2), the lipids together with the dissolved tacrolimus were
adsorbed on the surface of the mesoporous silica particles
which resulted in a fast release. According to the above results,
formulation No. 3 was selected as the most optimum one for
further studies.
The in vitro drug release data of SLH (formulation No.3) were
fitted very well to first-order kinetic model (see Table 2), which
indicated a diffusion-controlled mechanism of finite dosed drug
delivery device. The release of tacrolimus from SLH was a two-
phase process, ie, (1) diffusion of tacrolimus through the
mesoporous channels to the surface of silica carrier, and (2)
release of tacrolimus to the medium. Phase 1 was obviously
the rate-control step of complete drug release process.The pos-
sible drug release process was depicted and illustrated in Fig. 5.
For drug-loaded mesoporous silica, the organic solvent used
was completely removed after drug loading, tacrolimus was
adsorbed on the inner surface of the channels and presented
at a highly dispersing state. The release medium penetrated
into the mesoporous channels just after coming into contact
with the medium, and drug molecules diffused through the
medium-filled channels, which led to a fast drug release. While
for the SLH, the situation was obviously different due to fact
that the mesopores were filled with the mixed lipid that in-
hibited both the penetration of medium inward and the release/
diffusion of tacrolimus outward. Although the water-soluble
lipid (Gelucire 50/13) was readily dissolved into the release
medium, the diffusion of tacrolimus through the mesoporous
channels filled with the residual water-insoluble lipid matrix
was still relatively slower (low diffusion coefficient) com-
Fig. 4 – The in vitro release of tacrolimus from various formulations of drug loaded SLH (n = 3). The effect of the ratios of
tacrolimus to mixed lipids (Compritol 888 ATO : Gelucire 50/13 = 7 : 3 and mixed lipids : silica = 1 : 3) on in vitro drug release
(A), the effect of the ratios of Compritol 888 ATO to Gelucire 50/13 (tacrolimus : mixed lipids = 1 : 10 and mixed lipids :
silica = 1 : 3) on in vitro drug release (B) and the effect of the ratios of mixed lipids to mesoporous silica (Compritol 888 ATO :
Gelucire 50/13 = 7 : 3 and tacrolimus : mixed lipids = 1 : 10) on in vitro drug release (C) .
Table 2 – The release patterns of tacrolimus loaded SLH.
Release pattern Fitting equation R2
First order Ln(1-Q) = 0.1973t-0.1094 0.9939
Higuchi Q = 21.955t1/2 + 7.4484 0.8528
Korsmeyer–Peppas Q = 5.5596t0.94 0.8715
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pared to that through the medium-filled channels like in the
case of drug-loaded mesoporous silica.
3.3. Properties of the powder
3.3.1. Density
Powder densities, including true density, bulk density and tap
density, of mesoporous silica, SLH, and LBDDS were listed in
Table 3. It could be seen that mesoporous silica had the most
significant difference between the bulk density and the tap
density to the true density, followed by SLH and LBDDS powders.
3.3.2. Flowability
To the best of our knowledge, flow behavior of the powders is
a major concern in handling and processing operation such
as flow from hoppers and silos, transportation, mixing com-
pression and packaging [40], and it is also important to decide
the dose uniformity of drug preparations. The compressibil-
ity index and the closely related Hausner ratio have become
the simple and popular methods to predict the flow proper-
ties of powder according to USP 35. The values of the Carr’s
index and Hausner ratio of mesoporous silica, SLH, and LBDDS
were also determined and presented in Table 3. According to
the specification of flowability in USP 35, the LBBDS with a
Hausner ratio of 1.09 and Carr’s Index of 8.45, and the pure
silica with a Hausner ratio of 1.25 and Carr’s Index of 20.0 were
classified as good-flowing and fair-flowing, respectively. While
the SLH had an intermediate flowability with a Hausner ratio
lower than 1.18 (1.16) and Carr’s Index lower than 15 (13.75),
which was also classified as good-flowing. The angle of repose
measured by tilt method gave a direct indication to the
flowability of the powders tested (Fig. 6). We could draw the
conclusion that the order of the flowability was
LBDDS > SLH > pure mesoporous silica, which was in accor-
dance to the results of Hausner ratio and Carr’s Index.
3.3.3. Compressibility
The slope of compress curve of SLH calculated by Heckel equa-
tion was 0.16, which was bigger than that of mesoporous silica
(0.10). According to the theory of Heckel equation, the slope
reflects the degree of plastic deformation. The bigger the slope
is, the better the compressibility is. As shown in Fig. 7 the tablet
obtained from SLH showed smooth surface and intact appear-
ance, while the tablet obtained from mesoporous silica had
relatively rough surface and capped just after withdrawal from
the die. It could be directly perceived that SLH had better
compactibility than mesoporous silica.
At a low density and rigid inorganic powder, mesoporous
silica has poor flowability and compressibility, which could
hardly be compressed into tablet at all. LBDDS was wax-like
solid at room temperature, which could be readily crushed and
grinded into fine powder. What is more, the LBDDS powder has
a good flowability and apt to aggregate during storage. In fact,
Compritol 888 ATO has various properties, such as the lower
shear stress, appropriate melting point, high specific surface
area, amphiphilic and film forming tendency, and the use of
Fig. 5 – The processes of drug loading and drug release from the drug-loaded SLH. Phase 1: diffusion of tacrolimus through
the mesoporous channels to the surface of silica carrier; Phase 2: release of tacrolimus to the media.
Table 3 – Density and flow properties of mesoporous silica, SLH and LBDDS.
Bulk density mg/cm3 Tap density mg/cm3 Ture density mg/cm3 Carr’s index Hausner ratio
Mesoporous silica 298 373 1340 20.00 1.25
LBDDS 441 482 1080 8.45 1.09
SLH 448 519 1480 13.75 1.16
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lipid as lubricant initially in pharmaceutics could be traced back
to the 1980s [41,42]. As a wax-like powder with low melting-
point, Compritol 888 ATO also played the role of binder in this
study. The SLH powder was almost the same as mesoporous
silica in appearance. However, the key differences between
mesoporous silica and SLH powder were that SLH had a good
flowability and compressibility which could be compressed into
tablet easily. No wonder the good flowability and compress-
ibility of SLH powder are mainly due to the good lubricity and
plasticity of Compritol 888 ATO absorbed on the surface of the
silica.
4. Conclusion
In this study, we provided a novel method to prepare a sus-
tained release powder containing tacrolimus by employing
mesoporous silica as the carrier to adsorb drug-loaded LBDDS.
Using this method, the low melting-point, wax-like LBDDS could
be transformed to a rigid solid powder with good flowability,
compressibility and compactibility. By the combination of lipids
and mesoporous silica, we successfully obtained a kind of
sustained-release powder, and the stability of LBDDS under
challenge condition could also be obviously improved. Such
organic solvent-free technique supplied a novel, simple, low
cost, ecologically friendly and easy to obtain at industrial scale
method to prepare tacrolimus solid sustained-release powder,
the powder we obtained had a better stability and micromeritic
properties, which could be made into dry suspension, gran-
ules, capsules, and tablets according to the clinical requirements.
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